市场调查报告书
商品编码
1184241
生命科学分析中AI全球市场规模,份额和行业趋势分析报告:按最终用户(製药,医疗器械,生物技术,其他),应用,部署,组件,地区展望和预测2022-2028Global AI In Life Science Analytics Market Size, Share & Industry Trends Analysis Report By End-user (Pharmaceutical, Medical Devices, Biotechnology and Others), By Application, By Deployment, By Component, By Regional Outlook and Forecast, 2022 - 2028 |
在预测期内,生命科学分析领域人工智能的全球市场规模预计将以 10.9% 的复合年增长率增长,到 2028 年达到 25 亿美元。
此外,由于药物发现和临床试验中对降低成本和提高运营效率的需求不断增长,人工智能在生命科学领域的应用也在取得进展。 数据驱动的 AI 的快速发展、深度学习的技术进步以及对机器人自主性不断增长的需求正在推动 AI 在分析中的应用。
这种采用主要是由于研发成本高、临床试验成功率低以及对罕见病的关注度增加等变数导致的药物发现过程效率低下。 机器学习技术改善候选人招聘流程、数据存储和数据分析的能力有望推动市场扩张。
COVID-19 影响分析
广泛使用 AI 来跟踪大量大规模临床试验的结果进一步促进了对 AI 和类似技术的更多需求。 此外,大流行期间电子数据捕获(EDC)系统等技术发展使文件控制监控和远程电子签名成为可能,进一步加快了审判进程。 因此,它对许多製药公司快速开发高效候选药物有很大帮助。 因此,COVID-19 大流行对生命科学分析领域的 AI 市场产生了积极影响。
市场增长因素
个性化医疗和精准医疗日益受到关注
人工智能技术正在对个性化医疗和精准医疗的发展领域产生重大影响。 与传统的预测建模或机械假设不同,人工智能解决方案在逻辑上开发了最佳药物组合。 这些药物组合是通过对特定于被评估疾病的保守数据集进行有效分析,从真实和成功的实验证据中开发出来的。 因此,通过扩大 AI 和 ML 在个性化和精准医疗发展中的范围,生命科学分析中的 AI 市场将会增长。
扩大人工智能在药物发现中的应用
许多製药和生物製药公司正在加大对人工智能係统的投资。 它们被广泛用于改善疾病靶标识别、从头开始的药物设计、毒性和疗效预测以及化学筛选。 人工智能深度学习也非常适合药物开发,因为它能够从原始数据中提取基本特征,而不管数据集大小。 这进一步推动了人工智能的采用,从而推动了人工智能在生命科学分析市场的扩张。
市场约束
重要信息的安全和隐私问题
研究机构、软件公司和临床研究组织 (CRO) 之间日益共享的数据库增加了敏感数据洩露的风险。 频繁访问信息还会将敏感的患者信息暴露给外人。 应用分析解决方案并遵守隐私政策是生物製药和製药公司面临的主要挑战,因为大多数数据都是以电子方式管理的。 因此,药物开发研究和开发可能会受到各种政府法规变化的限制。
最终用户的观点
基于最终用户,生命科学分析市场中的 AI 细分为医疗设备、製药、生物技术等。 2021 年,製药领域将在生命科学分析领域占据 AI 市场的最高收入份额。 在药物发现、临床试验和製造中越来越多地采用人工智能工具是推动这一领域增长的主要因素。 这些工具显着降低了成本和周期时间,同时改善了临床结果。
应用展望
根据应用,生命科学分析市场中的 AI 细分为研发、销售和营销支持、供应链分析等。 在 2021 年生命科学分析的 AI 市场中,供应链分析领域增长显着。 製药和生物製药公司的供应链包括生产药品所需的一系列复杂步骤。 供应链的重要部分包括采购和供应原材料、製造和分销流程,以及开发药物的交付。
部署前景
根据部署,生命科学分析中的 AI 市场分为本地和云端。 2021 年,云业务在生命科学分析领域的 AI 市场中占据了最大的收入份额。 云服务的不断发展、互联网的普及和基于云的技术的采用是推动这一领域增长的主要因素。 部署基于云的 AI 服务具有通过消除对专用数据中心的需求而降低投资成本的优势。
组件视角
基于组件,生命科学分析市场中的人工智能被细分为软件、硬件和服务。 2021 年,硬件部分在生命科学分析市场的 AI 中取得了显着的增长。 在生物医学工程领域,正在集成基于人工智能的系统,以帮助完成任何微创手术的诊断和实时图像生成等任务。 此外,预配置硬件解决方案的应用有助于支持医务人员在医疗实践、疗养院和医院的关键工作。
区域展望
按地区划分,对北美、欧洲、亚太地区和 LAMEA 的生命科学分析市场中的 AI 进行了分析。 2021 年,北美部分在生命科学分析市场中的 AI 中占据了最大的收入份额。 该地区高水平的数字素养以及生命科学领域的发展正在推动该领域的增长。 此外,政府举措的增加以及製造商与政府机构之间合作的加强进一步推动了人工智能解决方案的需求和整合。 此外,该地区的许多医疗机构已经开始部署人工智能解决方案来简化他们的工作流程。
合作伙伴关係是市场进入者采取的主要策略。 根据基数矩阵中的分析,Microsoft是生命科学分析领域 AI 市场的领先先驱。 Oracle Corporation、Accenture PLC 和 IBM Corporation 等公司是生命科学分析领域 AI 市场的领先创新者。
The Global AI In Life Science Analytics Market size is expected to reach $2.5 billion by 2028, rising at a market growth of 10.9% CAGR during the forecast period.
The term artificial intelligence (AI) refers to a heavily data-driven technology. It is frequently used in the R&D departments of the life sciences sector to provide insightful data from fragmented sources. Though the use of AI technologies and tools is still in its early phases in the life sciences sector, yet it is facilitating companies to develop strategic technological skills for establishing a competitive edge.
Since it can deliver data quickly, precisely, and reliably, AI is gaining acceptance in the analytics field. Because of this, businesses are becoming keener to invest in incorporating AI algorithms into analytical solutions. The accelerating development of new technologies, such as artificial intelligence, and their widespread use across a variety of industries have increased demand for AI in the life sciences sector.
In addition, the application of AI in life sciences is also growing as there is a rising need to reduce costs and improve operational efficiencies in drug discovery and clinical trials. The rapid development of data-based AI, technological advancements in deep learning, and the growing requirement to achieve autonomy in robotics has propelled the implementation of AI in analytics.
This adoption is mainly driven by the inefficiency of the drug discovery process as a result of variables such as high costs of research and development, low success rates in clinical trials, and rising attention to rare diseases. The ability of machine learning technology to improve candidate recruitment processes, data storage, and data analytics is expected to drive market expansion.
COVID-19 Impact Analysis
The extensive help of AI in keeping track of the results of numerous clinical trials on an expanded scale further helped in creating more demand for AI and similar technologies. Furthermore, the development of technologies like electronic data capture (EDC) systems during the pandemic enabled document management monitoring and remote electronic signatures and further accelerated the trial processes. As a result, this immensely helped many pharmaceutical companies in developing efficient drug contenders rapidly. Therefore, the COVID-19 pandemic positively impacted the AI in life science analytics market.
Market Growth Factors
Increasing Emphasis On Personalized Drugs And Precision Medicines
AI technology has greatly influenced the personalized medicine and precision medicine development sectors. Unlike the previous methods of predictive modeling and mechanistic assumptions, AI solutions logically develop optimal drug combinations. These drug combinations are developed from genuine and successful experimental proofs by efficient analysis of modest datasets that are specific to the disease being assessed. Hence, by extending the reach of AI and ML in the development of personalized drugs and precision medicines, AI in life science analytics market is bound to grow.
Growing Application Of Ai In Drug Discovery
Many pharmaceutical and biopharmaceutical companies have increased their investments in artificial intelligence systems as these extensively help in improving the identification of disease targets, designing of medication from the first step, toxicity, potency predictions, and chemical screening. In addition, deep learning enabled by AI is well suited for drug development because of its ability to extract essential features from unprocessed data, regardless of the dataset size. . This has further helped the adoption of AI and thus boosts the expansion of AI in life science analytics market.
Market Restraining Factors
Concerns Regarding The Safety And Privacy Of Crucial Information
The rising number of database sharing among research institutions, software companies, and clinical research organizations (CROs) presents a high risk of data leaks of confidential status. Frequent access to information may also result in the leakage of sensitive patient information to unofficial individuals. Since the majority of data is being maintained electronically, the application of analytics solutions and privacy policies compliance laws pose a significant challenge for biopharmaceutical and pharmaceutical companies. As a result, the R&D of drug development may get restricted by different governmental regulation shifts.
End-User Outlook
On the basis of end-user, the AI in life science analytics market is fragmented into medical devices, pharmaceutical, biotechnology, and others. The pharmaceutical segment acquired the highest revenue share in the AI in life science analytics market in 2021. The rising implementation of AI tools in drug discovery, clinical trials, and manufacturing are the primary factors that are advancing the growth of the segment. These tools significantly decrease the costs and cycle times while improving clinical outcomes.
Application Outlook
Based on application, the AI In life science analytics market is segmented into research & development, sales & marketing support, supply chain analytics, and others. The supply chain analytics segment witnessed a considerable growth rate in the AI In life science analytics market in 2021. The supply chains of pharmaceutical and biopharmaceutical companies involve an intricate set of steps that are necessary for the production of drugs. Some prominent parts of the supply chain include raw materials' sourcing and supply, manufacturing and distribution processes, and delivery of developed medications.
Deployment Outlook
On the basis of deployment, the AI In life science analytics market is divided into on-premise and cloud. The cloud segment recorded the maximum revenue share in the AI In life science analytics market in 2021. Increased development of cloud services, penetration of the internet, and adoption of cloud-based technologies are the main factors propelling the growth of the segment. Implementation of cloud-based AI services is beneficial as they eliminate the requirement for dedicated data centers and hence lower the cost of investment.
Component Outlook
Based on component, the AI In life science analytics market is categorized into software, hardware, and services. The hardware segment procured a remarkable growth rate in the AI In life science analytics market in 2021. In the field of biomedical engineering, AI-based systems are integrated to help in tasks like diagnoses and live image production for any minimally invasive surgeries. The further application of preconfigured hardware solutions aid in supporting crucial jobs of medical staff in medical practices, care facilities, and hospitals.
Regional Outlook
On the basis of region, the AI In life science analytics market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment garnered the maximum revenue share in the AI In life science analytics market in 2021. The higher digital literacy, along with developments in the life science field in the region, has propelled the growth of the segment. In addition, the rising number of government initiatives and increasing collaborations between manufacturers and government bodies have further boosted the demand and integration of AI solutions. Many healthcare institutions in the region have also started adopting AI solutions to organize their workflows.
The major strategies followed by the market participants are Partnerships. Based on the Analysis presented in the Cardinal matrix; Microsoft Corporation is the major forerunner in the AI In Life Science Analytics Market. Companies such as Oracle Corporation, Accenture PLC, and IBM Corporation are some of the key innovators in AI In Life Science Analytics Market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Wipro Limited, Lexalytics, Inc., Databricks, Inc., SAS Institute, Inc., Sisense, Inc., IQVIA Holdings, Inc., IBM Corporation, Microsoft Corporation, Oracle Corporation, and Accenture PLC.
Strategies deployed in AI In Life Science Analytics Market
Nov-2022: IQVIA teamed up with Clalit, a health services organization in Israel, with an aim to launch the first prime site in the country. Under the collaboration, the capabilities of real-world research, genomics, data, and clinical trial delivery of both companies would be combined, which would allow focus on the delivery of data-driven trials and precision medicine.
Sep-2022: Wipro announced the launch of an AI-enabled Cath lab, to assist with cardiovascular disease. The product contains AutoRight technology, which allows the delivery of precision healthcare, with an aim of minimization of risk and surgical procedures. Cath lab enables intelligent imaging systems to help cardiologists to give appropriate therapies and treatments.
Aug-2022: Databricks make an enhancement to its Brickbuilder Solutions for Healthcare and Life Sciences. New manufacturing and financial services in healthcare would be added, with an aim to reduce cost and elevate time to value across the data transformation journey. Brickbuilder Solutions comprises of AI and data solutions that are expertly designed to address industry-specific business requirements.
Mar-2022: Wipro partnered with Pandorum Technologies, a biotechnology company. Under the partnership, the expertise of Pandorum in regenerative medicines would be combined with the capabilities of Wipro in Artificial Intelligence (AI). This would fuel growth, elevate innovation as well as transform business processes.
Mar-2022: IQVIA released a new workflow tool OCE+, an advancement to its life science customer engagement platform. The tool provides AI-driven recommendations for healthcare professionals (HCP) and this tool would be able to make more informed and smarter decisions. The product maximizes productivity, expands ROI, and advances HCP experiences.
Oct-2021: Oracle took over Cerner, a provider of healthcare solutions, to get more coordinated care and seamless technology in solutions for healthcare. This acquisition would combine the clinical abilities of Cerner with Oracle's enterprise analytics, platform, and automation expertise and aim to expand its global footprint.
Sep-2021: IQVIA added AI-powered technologies to advance the capabilities of Medical Information (MI)services, which comprise Safety and Quality offerings providing customers with end-to-end services and technology. IQVIA's MI Contact Center services would be available in around 170 countries in 50 different languages with highly skilled agents solving to queries.
Apr-2021: IQVIA Holdings Inc. completed the acquisition of Q2 Solutions, clinical laboratory services organization. This acquisition would strengthen its product offering with industry leading suite of services that includes supply chain, biorepository, project management, biospecimen, comprehensive testing as well as consent tracking solutions used in clinical trials.
Mar-2021: Oracle partnered with Saama to provide AI-Enabled Applications to Life Sciences Industry to Advance Clinical Trials. Under the partnership, the smart application of Saam would be combined with the Oracle platform, to provide clinical trial teams with real-time insight. Additionally, this would enable an integrated user experience, agility, and fast outcomes from clinical applications.
Jan-2021: SAS announced the acquisition of Boemska, an IT Services and IT Consulting company. With This acquisition, the acquired technology would be integrated with SAS Viya which would allow the execution and development of decisions and models using no-code and low-code technologies, to perform specific tasks such as decision-making related to a medical event, identifying a manufacturing defect, anticipating fraud and more.
Jan-2020: Accenture came into collaboration with Google Cloud, a suite of cloud computing services. Under the collaboration, artificial intelligence and the cloud of Google would be combined with life sciences services and platforms of Accenture, to assist the life sciences organizations, to make data more secure, valuable, and accessible.
Feb-2019: IQvia announced the acquisition of Linguamatics, a provider of NLP-based text mining for life science and healthcare. With this addition of the AI-based natural language processing solution, the company would be able to uplift the capabilities to help life science and offer better value-based care and good decision-making.
Market Segments covered in the Report:
By End-user
By Application
By Deployment
By Component
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures